An interventional study of salicylic acid wart patches in Common Warts and Plantar Warts, sponsored by Langsteiner sp. z o.o.. Completed at 1 site in Poland. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2025-09-08.
Sponsored by Langsteiner sp. z o.o. · Not applicable, Interventional, and Treatment
Common and plantar warts are a type of skin lesion caused by infection with the human papilloma virus. The incidence of warts is relatively high, with an estimated few to several per cent of the adult population affected. An even higher incidence of dermal warts is reported in the child and adolescent population, where it reaches nearly twenty per cent. The human papilloma virus (HPV) multiplies in the epidermal cells, leading to the formation of a skin lesion with a hyperkeratotic, uneven surface, called a wart. HPV infection can lead to various types of warts: including common warts, plantar warts, flat warts or condyloma acuminatum. Warts belong to skin lesions of a benign and self-limiting nature. Because of this, treatment of warts is often not applied. However, it is necessary to emphasise that warts, including in particular plantar warts, can be a source of pain as well as lead to psychological discomfort for the patient. Additionally, untreated warts are a potential source of subsequent infections.
For this reason, a variety of methods are used to treat warts, with the primary aim of removing the layer of diseased epidermis, as well as limiting the spread of the virus. The methods used to treat warts can be divided according to the nature of the agent used in the treatment - physical or chemical. Physical methods include cryotherapy, photodynamic therapy and surgical or laser wart removal. Chemical methods for the treatment of warts will be the use of ointments and solutions of substances such as salicylic acid, 5-fluorouracil, glycolic acid or purine acid. In addition, the treatment of warts also includes methods based on an occlusive action, involving the use of a barrier that shields the skin lesion and stops the spread of the virus.
This protocol concerns a study of salicylic acid wart patches. The aim of the study is to determine the efficacy and safety of their use in the treatment of common and plantar warts. The patches allow covering the lesion and the salicylic acid contained in them at a concentration of 40% has a keratolytic action allowing exfoliation of excessive epidermal proliferation caused by HPV infection. In addition, the mass of the product includes lanolin, which has an epidermal softening effect. The patches are intended for a patient population over six years of age, with common and plantar warts. The primary endpoints analysed in the study will be reduction in lesion size (assessed by dermatoscopic measurement), change in the number of warts in the area of the main wart-like lesion, occurrence of further dermal wart-like lesions in the treated area and incidence of adverse reactions. In addition, secondary endpoints to be analysed are reduction in lesion size (users' visual assessment), reduction in lesion visibility (users' visual assessment) and usability of the device.
171 studies on the registry are indexed under Warts; 35 are open to participants now.
This study's enrollment of 30 is below the median of 70 across 155 interventional studies indexed under Warts.
Browse Warts studies →This is the only study on the registry with Langsteiner sp. z o.o. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: salicylic acid wart patches
The wart patches contain the auxiliary therapeutic substance salicylic acid at a concentration of 40%, which causes chemical exfoliation, removing the exfoliated skin. Salicylic acid softens the keratinised skin, making it easier to remove. The remedial process leads to the removal of the wart by exfoliation. The wart should disappear after about 7 days of using the patch. The treatment can be prolonged up to 21 days. The wart patch is intended for the treatment of common warts and plantar warts. The mechanism of action of the product is the barrier and protective action of the patch, reducing the possibility of spreading viral infection and, as an auxiliary, to exfoliate keratinised epidermis, accelerating the skin renewal process.
reduction in the size of the lesion
reduction in the size of the lesion assessed by measuring with a dermatoscope
Time frame: 30 minutes (single visit)
change in the number of warts in the area of the main wart-like lesion
change in the number of warts in the area of the main wart-like lesion as assessed by the dermatologist
Time frame: 30 minutes (single visit)
occurrence of further dermal wart-like lesions in the treated area
occurrence of further dermal wart-like lesions in the treated area as assessed by the dermatologist
Time frame: 30 minutes (single visit)
Adverse events
Adverse events occuring during treatment of warts
Time frame: 30 minutes (single visit)
reduction in lesion size
reduction in lesion size according to users' visual assessment
Time frame: 30 minutes (single visit)
reduction in the visibility of the lesion
reduction in the visibility of the lesion, user's visual assessment
Time frame: 30 minutes (single visit)
usability of the device
usability assessed with a questionaire
Time frame: 30 minutes (single visit)
Ran from May 2025 to primary completion in Jul 2025, 2 months.
Of 28 interventional studies with no phase under Warts, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.